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Regions of severe oxygen deprivation (hypoxia) arise in tumors due to rapid cell divi-
sion and aberrant blood vessel formation. The hypoxia-inducible factors (HIFs) mediate 
transcriptional responses to localized hypoxia in normal tissues and in cancers and can 
promote tumor progression by altering cellular metabolism and stimulating angiogenesis. 
Recently, HIFs have been shown to activate specific signaling pathways such as Notch and 
the expression of transcription factors such as Oct4 that control stem cell self renewal and 
multipotency. As many cancers are thought to develop from a small number of transformed, 
self-renewing, and multipotent “cancer stem cells,” these results suggest new roles for 
HIFs in tumor progression.Solid tumors are known to contain poorly vascularized 
regions characterized by severe hypoxia (oxygen dep-
rivation), low pH, and nutrient starvation (Carmeliet and 
Jain, 2000; Pouyssegur et al., 2006). Tumor hypoxia is 
typically associated with poor patient prognosis, partly 
because low oxygen levels reduce the effectiveness of 
radiation therapy, which kills tumor cells by generating 
reactive oxygen species. Over the past decade, work 
from many laboratories has indicated that hypoxic micro-
environments contribute to cancer progression by acti-
vating adaptive transcriptional programs that promote 
cell survival, motility, and tumor angiogenesis. Recent 
reports describing molecular connections between oxy-
gen-regulated transcription factors and pathways known 
to control stem cell function suggest a new mechanism 
whereby hypoxia-induced transcription factors may 
drive tumor growth through the generation or expansion 
of tumor-initiating cells or cancer stem cells. Here, we 
discuss how these results add an important new facet to 
our traditional view of hypoxia and cancer.
Many of the cellular responses to hypoxia are medi-
ated through changes in gene expression. The tran-
scription factors primarily responsible for these changes 
are the hypoxia-inducible factors (HIFs), the biology of 
which has been reviewed elsewhere (Pouyssegur et al., 
2006; Semenza, 2003). Briefly, HIFs are members of the 
bHLH-PAS family of proteins and bind to canonical DNA 
sequences (hypoxia regulated elements, or HREs) in the 
promoters or enhancers of target genes. They consist 
of an α (HIF-α) and a β (HIF-β, or ARNT) subunit and 
activate the expression of at least 150 genes encoding proteins that regulate cell metabolism, survival, motility, 
basement membrane integrity, angiogenesis, hemat-
opoiesis, and other functions. Regulation of HIF activity 
is mediated primarily through the stability of the α subu-
nit: under conditions of abundant oxygen (>8%–10%), 
HIF-α proteins are translated but rapidly degraded. 
HIF-α degradation is triggered by the hydroxylation of 
two key proline residues in its highly conserved oxygen-
dependent degradation domain (ODD). These hydroxy-
lation events, catalyzed by specific proline hydroxylase 
(PHD) enzymes, are necessary and sufficient for bind-
ing to the Von Hippel-Lindau tumor suppressor protein 
(pVHL), the recognition component of an E3 ubiquitin 
ligase that targets the HIFs to the 26S proteasome for 
destruction. As oxygen levels decrease below 8%–10%, 
HIF-α proteins become increasingly stabilized, although 
the nature of the oxygen-sensing mechanisms regulat-
ing these events remains controversial. Once stabilized, 
HIF-α proteins bind to constitutively expressed ARNT 
(HIF-β) subunits in the nucleus, bind to DNA, and acti-
vate transcription through interactions with coactivators, 
including CBP/p300. Interestingly, binding to CBP/p300 
is regulated by hydroxylation of a conserved asparagine 
residue in the HIF-α C-terminal domain (Pouyssegur et 
al., 2006).
HIF-1α and HIF-2α share a high degree of sequence 
identity, underscored by their shared ability to het-
erodimerize with ARNT and bind to HREs to activate 
transcription of common, as well as some unique, tar-
get genes (Raval et al., 2005 and references therein). 
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tous fashion, HIF-2α expression is restricted to particu-
lar cell types, including vascular endothelial cells, neural 
crest cell derivatives, lung type II pneumocytes, liver 
parenchyma, cardiomyocytes, and interstitial cells in the 
kidney (Wiesener et al., 2003). Genetic ablation experi-
ments in mice have demonstrated that all HIF subunits 
tested to date are essential for embryonic development 
and survival. These analyses have led to the view that 
oxygen gradients develop as a function of limited dif-
fusion in rapidly growing tissues. The inability to mount 
proper transcriptional responses to physiological 
hypoxia in HIF-deficient embryos results in developmen-
tal arrest and death. The specific phenotypes observed 
in mutant embryos differ depending on which HIF subu-
nit is mutated, but alterations in cell survival, differentia-
tion, and tissue angiogenesis have been reported in mice 
lacking ARNT, HIF-1α, or HIF-2α (Ramirez-Bergeron and 
Simon, 2001).
In contrast to the exquisitely regulated HIF activation 
observed in embryos, the highly disorganized vascu-
lar supply of solid tumors typically produces regions of 
severe hypoxia or anoxia closely abutting well-oxygen-
ated areas (Pouyssegur et al., 2006). The consequent 
stabilization of HIF proteins in hypoxic cancer cells is 
thought to promote tumor progression, in large part by 
inducing the localized expression of specific target genes 
encoding vascular endothelial growth factor (VEGF), 
glycolytic enzymes (PGK, ALDA), glucose transporters 
(GLUT1), and proteins regulating motility (lysl oxidase) 
and metastasis (CXCR4, E-cadherin), among others (Fig-
ure 1) (Semenza, 2003). Many tumor studies support this 
view: for example, subcutaneous fibrosarcomas gen-
erated from HIF-1α deficient, Ras-transformed murine 
embryonic fibroblasts (MEFs) grew more slowly than their 
HIF-replete controls (Ryan et al., 2000). Similar xenograft 
experiments with ARNT-deficient hepatoma cells also 
showed a clear decrease in tumor growth compared to 
ARNT-expressing counterparts (Maxwell et al., 1997). HIF 
activity can also be induced or enhanced 
in some transformed cells through oxy-
gen-independent oncogenic signaling 
pathways, including those regulated by 
IGF2/IGF1R, TGF-α/EGFR, and PI3K/
Akt (Semenza, 2003). Expression of 
the HIF-α proteins in human tumor cells 
often correlates with a poor progno-
sis: for example, high-grade pediatric 
astrocytomas display greater HIF-2α 
expression than low-grade astrocyto-
mas (Khatua et al., 2003). Interestingly, 
HIF-1α and HIF-2α share some target 
genes, including those encoding VEGF, 
GLUT1, and ADM-1; in contrast, genes 
encoding glycolytic enzymes (PGK1, 
ALDA) are unique HIF-1α targets, and 
those encoding TGF-α and cyclin D1 
appear to be unique HIF-2α targets, 
at least in certain cell types (Figure 1) 
(Raval et al., 2005). Although much remains to be deter-
mined, extensive analyses have solidified the central con-
cept that HIF activity in cancer cells drives tumor progres-
sion by inducing the expression of genes that promote 
adaptation to hypoxia. The degree to which HIF activation 
in tumor stromal cells, such as infiltrating macrophages 
and leukocytes, contributes to tumor angiogenesis and 
progression is an important question currently under 
investigation.
Evidence from a variety of experimental systems has 
shown that hypoxia also regulates the proliferation and 
differentiation of different stem cell populations, includ-
ing embryonic stem (ES) cells, neuronal and neural crest 
stem cells, hematopoietic stem cells (HSCs), and tro-
phoblast stem cells. The direct role of HIFs in controlling 
these effects has been demonstrated in some, but as yet 
not all, of these stem cell types. The hypoxic responses 
of different stem cell populations is consistent with the 
idea that oxygen levels may be an important component 
of particular stem cell “niches” and that HIF activity can 
regulate the defining features of stem cells, including self 
renewal and multipotency. In the following sections, we 
will discuss the mechanisms by which hypoxia and HIFs 
mediate these effects and also discuss their implica-
tions for cancer biology. Finally, we propose a molec-
ular model for how HIFs may promote the adoption of 
stem cell characteristics by differentiated hypoxic tumor 
cells.
Hypoxia, HIFs, and Stem Cells
Stem cell niches are defined as particular locations or 
microenvironments that maintain the combined properties 
of stem cell self renewal and multipotency. In the fruit fly 
Drosophila melanogaster and the nematode Caenorhabdi-
tis elegans, germ stem cell niches have been described in 
remarkable detail. Germ stem cells in the Drosophila ovari-
ole and testis require physical interaction with supporting 
cap or hub cells, respectively, to retain stem cell identity 
Figure 1. Traditional View of HIFs in Tumor Progression
Tumor cells residing closer to blood vessels are relatively well oxygenated (red), whereas 
those at more distant sites are hypoxic (blue). Stabilization of HIF-α proteins in these cells 
stimulates the expression of numerous target genes encoding factors that mediate adapta-
tion to hypoxic stress. Some target genes are regulated specifically by HIF-1α, such as those 
encoding the glycolytic enzymes ALDA and PGK, whereas others are specific targets of HIF-
2α, such as those encoding TGF-α and cyclin D1. Most HIF target genes are regulated by 
both HIF-1α and HIF-2α, including those encoding the angiogenic cytokine VEGF and the 
glucose transporter GLUT1 (Raval et al., 2005, and references therein).466 Cell 129, May 4, 2007 ©2007 Elsevier Inc.
(Ohlstein et al., 2004). In the C. elegans gonad, the niche 
consists primarily of a single distal tip cell whose long cyto-
plasmic processes make extensive physical contact with 
germ stem cells (Morrison and Kimble, 2006). In mam-
mals, spatially defined stem cell niches have also been 
identified in multiple tissues, including the gonad (Seydoux 
and Braun, 2006), skin (Fuchs, 2007), intestine (Sancho 
et al., 2004), and brain (Merkle and Alvarez-Buylla, 2006), 
although in some cases the cells comprising the niche 
have not yet been explicitly identified (Joseph and Morri-
son, 2005). A combination of genetic and molecular analy-
ses has identified a number of molecular factors—typically 
supplied by the supporting cells of the niche—that con-
trol stem cell identity. These factors include components 
of the BMP, Notch, Wnt, JAK-STAT, and Sonic hedgehog 
(Shh) signaling pathways, which provide intercellular cues 
that regulate stem cell identity and differentiation (Sancho 
et al., 2004; Joseph and Morrison, 2005; Ohlstein et al., 
2004; Fuchs, 2007). These signaling functions have been 
highly conserved through evolution. For example, altered 
Notch signaling affects the function of a variety of mam-
malian stem cells (hematopoietic, intestinal, and skin), as 
well as intestinal stem cells in Drosophila and germ stem 
cells in C. elegans (Joseph and Morrison, 2005; Ohlstein et 
al., 2004; Ohlstein and Spradling, 2006). Coordinate regu-
lation of genes controlling stem cell function is achieved in 
part through the activity of chromatin remodeling factors, 
including Bmi-1 and PRC2 (Joseph and Morrison, 2005; 
Lee et al., 2006).
Local oxygen concentrations can directly influence stem 
cell self renewal and differentiation. One attractive hypoth-
esis is that stem cells, particularly in long-lived animals, 
might benefit from residing in hypoxic niches where oxida-
tive DNA damage may be reduced. Direct measurement of 
oxygen levels has revealed that bone marrow is, in general, 
quite hypoxic (?1%–2% O2) (Cipolleschi et al., 1993). Given 
the ongoing debate as to whether HSCs in bone marrow are 
associated with osteoblasts or sinusoidal endothelial cells 
(or both) (Kiel et al., 2005), it will be interesting to determine 
the oxygen concentrations in specific bone marrow sub-
domains, although such an experiment remains technically 
challenging. Wherever HSCs reside, their proliferation and 
function is clearly affected by oxygen. Danet et al. (2003) 
demonstrated that culturing human bone marrow HSCs 
under hypoxic conditions (1.5% O2) promoted their ability 
to engraft and repopulate the hematopoietic compartment 
of immunodeficient NOD/SCID mice (Danet et al., 2003). 
Similar results were obtained for hematopoietic progeni-
tors isolated from embryonic yolk sacs or generated from 
ES cells grown in three-dimensional embryoid bodies in 
vitro (Ramirez-Bergeron and Simon, 2001). These oxygen-
mediated effects are not unique to HSCs: culturing neural 
crest stem cells or neuronal stem cells under hypoxic con-
ditions (?5% O2) promotes their proliferation and skews 
cellular differentiation toward specific fates (Morrison et al., 
2000a; Studer et al., 2000). Differentiation of human pla-
cental cytotrophoblast cells is also directly influenced by 
hypoxia (Genbacev et al., 1997). Finally, Pahlman and col-leagues have demonstrated that hypoxic conditions confer 
a more immature phenotype on human neuroblastoma and 
breast cancer cell lines (Axelson et al., 2005).
Some of the effects of hypoxia on stem cell function are 
directly mediated by the HIF proteins. Targeted mutation 
of the ARNT subunit eliminates both HIF-1α and HIF-2α 
function and results in a decreased number of progenitor 
cells of all hematopoietic lineages in the embryonic yolk 
sac of Arnt−/− mouse embryos. This phenotype is recapitu-
lated when Arnt−/− ES cells are induced to form hematopoi-
etic progenitor cells in embryoid bodies in vitro (Ramirez-
Bergeron and Simon, 2001). Although Arnt-deficient mouse 
embryos display a variety of developmental abnormalities, 
they die at embryonic day (E) 9.5–E10.5 due to a defective 
placenta. Analysis of placentas from Arnt−/− (or HIF-1α−/−, 
HIF-2α−/− double) mutant mouse embryos revealed that 
HIF activity influences the differentiation of trophoblastic 
stem cells into either spongiotrophoblasts, which occupy 
a particularly hypoxic zone, or into trophoblast giant cells, 
which lie close to the oxygen-rich maternal spiral arteries 
(Cowden Dahl et al., 2005). The effects of HIF activity on 
trophoblast cell-fate determination have also been reca-
pitulated using trophoblast stem cell lines cultured in vitro. 
These experiments implicate the HIF proteins in the con-
trol of HSC and trophoblast stem cell function; future work 
will be necessary to determine their specific functions in 
other stem cell populations. To date, only a few HIF target 
genes that might confer these effects have been identified. 
Expression of the VEGF gene, in particular, accounted for 
many of the HIF-mediated effects on hematopoietic pro-
genitors (Ramirez-Bergeron and Simon, 2001), but there 
is little doubt that other factors and signaling pathways are 
involved.
Recent reports have identified new molecular mecha-
nisms by which HIFs directly modify cellular differentia-
tion and stem cell function. Lendahl, Poellinger, and col-
leagues reported that hypoxia blocked the differentiation of 
myogenic satellite cells, a myogenic cell line (C2C12), and 
primary neural stem cells in a Notch-dependent manner 
(Gustafsson et al., 2005). When Notch receptors interact 
with the Jagged or Delta family of ligands, two proteolytic 
cleavage events result in the release of the Notch intrac-
ellular domain from the plasma membrane and its trans-
port to the nucleus, where it forms a DNA-binding com-
plex with other coactivators including MAML, CSL, and 
p300, and activates target-gene expression (Bray, 2006). 
Using neurogenic rat embryonic carcinoma cells, the 
authors demonstrated that hypoxic treatment increased 
stabilization of the transcriptionally active Notch intracel-
lular domain and stimulation of Notch target genes Hes-1 
and Hey-2. Chromatin immunoprecipitation (ChIP) experi-
ments revealed that HIF-1α was physically recruited to a 
DNA-binding complex containing the Notch intracellular 
domain in hypoxic cells. Hypoxic induction of Notch target 
genes was dependent on the Notch intracellular domain 
and also required the functional C-terminal transactivation 
domain of HIF-1α, which interacts directly with p300/CBP. 
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to HIF-1α, as HIF-2α also augmented Notch target-gene 
expression in hypoxic A-498 renal carcinoma cells. Exactly 
how HIF-α proteins integrate into the Notch intracellular 
domain:MAML:CSL complex is not yet understood, nor is 
it known whether this response modulates the expression 
of all Notch target genes, or only a subset (Gustafsson et 
al., 2005).
Notch pathway signaling (Bray, 2006) has profound 
effects on cellular differentiation in Drosophila, C. elegans, 
and mammals, making the direct connection to HIF factors 
particularly intriguing. The results from Gustafsson et al. 
(2005) suggest that altered Notch signaling may underlie 
some of the developmental defects observed in HIF-defi-
cient embryos, and in adult cells and tissues (such as the 
chondrocyte growth plate) from which HIF-1α has been 
selectively deleted (Schipani et al., 2001). It is also strik-
ing that a primary effect of hypoxia, acting through Notch, 
was to inhibit the differentiation of a variety of cell types. 
Notch signaling is critical for the maintenance of undiffer-
entiated stem and progenitor cell populations in the mam-
malian intestinal crypt and also influences differentiation 
of mature enterocytes (Wilson and Radtke, 2006). Forced 
Notch activation in hematopoietic bone marrow or T cell 
progenitor cells also blocks differentiation and results in T 
cell acute lymphoblastic leukemia (Pear and Aster, 2004). 
It is interesting to note, however, that bone marrow-specific 
deletion of Jagged1 and Notch1 function does not deplete 
HSCs or disrupt hematopoiesis (Mancini et al., 2005), rais-
ing the possibility that other Notch receptors and/or lig-
ands are active in these cells. It is tempting to speculate 
that a stem cell residing in a hypoxic niche may require 
HIF-α proteins to fully activate Notch target genes that 
inhibit differentiation, thereby contributing to stem cell self 
renewal and multipotency. Testing this hypothesis directly 
will entail selective inactivation of HIF-α or Notch in specific 
stem cell populations in vivo. It is important to remember, 
however, that the effects of Notch signaling can be cell-
type dependent, as Notch activation actually promotes 
terminal differentiation in epidermal keratinocytes and cer-
tain neural stem cells (Morrison et al., 2000b; Wilson and 
Radtke, 2006).
Our laboratory recently reported that hypoxia regulates 
stem cell function through direct activation of specific HIF 
target genes. To determine the functional redundancy 
between HIF-1α and HIF-2α in embryonic development, 
we targeted a HIF-2α cDNA into the HIF-1α locus in murine 
ES cells, thereby replacing HIF-1α expression with HIF-2α. 
This “knockin” allele was designed to test the degree to 
which expanded HIF-2α expression, under the regulatory 
control of the HIF-1α locus, could complement a HIF-1α 
null mutation (Covello et al., 2006). As HIF-1α-deficient 
embryos die at E9.5–E10.5, we predicted that if HIF-2α 
was completely incapable of complementing HIF-1α func-
tion, a similar embryonic lethality would be observed in 
homozygous HIF-2a knockin embryos. Surprisingly, HIF-
2α knockin homozygotes were resorbed between E3.5 and 
E7.5. The few embryos recovered between E6.5 and E7.5 
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Subsequent analysis revealed that these phenotypes cor-
related with expanded expression of Oct4, a critical tran-
scriptional regulator controlling ES cell identity. Interest-
ingly, the ability of HIF-2α to regulate Oct4 expression is 
not shared with HIF-1α, as chromatin immunoprecipitation 
analysis revealed binding of only HIF-2α to hypoxic regula-
tory elements in the murine Oct4 promoter.
Oct4, Sox2, and Nanog form a transcriptional network 
that regulates a large number of genes associated with 
cellular differentiation in ES cells (Lee et al., 2006; Loh et 
al., 2006). Analyses of human ES cells revealed that all 
three factors occupy and activate genes that promote ES 
cell growth and self renewal while simultaneously repress-
ing genes that promote differentiation (Lee et al., 2006). 
In vivo, Oct4 is expressed in the inner cell mass of blasto-
cysts, from which ES cells are derived, and in the murine 
epiblast. Oct4 expression is downregulated in somatic cells 
around the time of gastrulation, but retained in primordial 
germ cells and, apparently, some adult stem cell popula-
tions (Tai et al., 2005). Subtle changes in Oct4 protein lev-
els have dramatic effects on ES cell differentiation: a 2-fold 
decrease in Oct4 expression induces ES cells to differenti-
ate into trophectoderm, whereas a 2-fold increase induces 
differentiation of mesodermal cell types (Niwa et al., 2000). 
Sustained Oct4 expression is incompatible with terminal 
differentiation of somatic cells, suggesting that expanded 
HIF-2α expression elevates Oct4 activity in homozygous 
HIF-2α knockin embryos and cells, thereby contributing to 
the observed phenotypes. Interestingly, HIF-2α-deficient 
embryos have severely reduced numbers of primordial 
germ cells, which require Oct4 for survival (Kehler et al., 
2004), consistent with a normal in vivo role of HIF-2α in 
regulating Oct4 expression and stem cell function.
The links between the HIFs, Notch, and Oct4 reveal spe-
cific molecular mechanisms whereby oxygen responses 
can inhibit differentiation and, possibly, promote stem cell 
identity. They also raise the possibility of crosstalk between 
hypoxia and other stem cell signaling pathways. Direct 
connections between BMPs or Shh pathways and the HIFs 
have not yet been demonstrated, although TGF-β has been 
reported to induce HIF-α stabilization by inhibiting PHD2, 
one of the proline hydroxylases that target HIF-α subunits 
for degradation under normal oxygen conditions (McMa-
hon et al., 2006). In addition, a recent paper describing 
physical interaction between β-catenin and HIF-1α sug-
gests at least one mechanism by which Wnt signaling 
might affect HIF activity in stem cells (Kaidi et al., 2007). 
Determining the degree of crosstalk, if any, between the 
HIFs and these important signaling networks in stem cells 
is an exciting prospect for future research.
Hypoxia and Cancer Stem Cells—A New Role  
for HIFs?
A number of experiments over the past decade support 
the idea that cancers can grow from a discrete subpopu-
lation of malignant cells with stem cell properties (cancer 
stem cells) (Huntly and Gilliland, 2005; Reya et al., 2001). 
These transformed cells 
are formally similar to nor-
mal stem cells in that they 
self renew and produce 
more committed progeni-
tor or “transit-amplifying” 
cells whose progeny dif-
ferentiate, albeit aber-
rantly, to produce the bulk 
of the tumor (Figure 2). To 
date, cells with these and 
other stem cell proper-
ties have been identified 
in human hematopoietic, 
brain, and breast cancers, 
and are likely to be found 
in other tumors (Huntly 
and Gilliland, 2005; Reya 
et al., 2001; Vescovi et al., 
2006).
Cancer stem cells typi-
cally represent a small frac-
tion of the total tumor, can 
be enriched on the basis of 
cell-surface marker expres-
sion, and generate serially 
transplantable tumors in 
recipient immunodeficient 
mice (Huntly and Gilliland, 
2005). Some cancer stem 
cells also express ATP-binding cassette (ABC) glycoprotein 
transporters at the cell surface, a trait shared with normal 
hematopoietic stem cells. These transporters effectively 
pump out vital dyes, resulting in a characteristic unlabeled 
“side population” of cells detected in FACs plots. Unfortu-
nately, these transporters also eliminate chemotherapeutic 
drugs, thereby promoting the multidrug resistance (MDR) 
observed in a large number of cancer cell lines (Comer-
ford et al., 2002). In patients with chronic myeloid leukemia, 
the expression of ABC transporter proteins may explain 
the persistence of transformed stem cells that are resist-
ant to the chemotherapeutic drug Gleevec, despite prior 
successful treatment with Gleevec and disease remission 
(Michor et al., 2005). The source of cancer stem cells is 
not entirely clear and may differ depending on the specific 
disease. Some experimental results are consistent with the 
idea that cancer stem cells can be derived from normal 
stem cells that have undergone oncogenic transformation, 
as described for human acute myeloid leukemic stem cells 
(Huntly and Gilliland, 2005). In contrast, it is possible that 
malignant progenitor cells, or even differentiated cells, can 
be induced to express the properties of self renewal and 
multipotency through mutation or altered gene activation 
(Krivtsov et al., 2006).
Two recent papers support the idea that stem cell 
characteristics can be imposed on more differentiated 
cell types through a surprisingly small number of genetic 
manipulations.
Takahashi and Yama-
naka demonstrated that 
directed expression of only 
four transgenes can con-
vert normal murine fibrob-
lasts (embryonic and adult) 
into cells closely resem-
bling ES cells (Takahashi 
and Yamanaka, 2006). Par-
ticular fibroblast cell clones 
engineered to express 
KLF4, Sox2, Oct4, and c-
Myc transgenes gained a 
striking ES-cell-like mor-
phology, expressed genes 
characteristic of ES cells, 
and (unlike fibroblasts) 
failed to senesce during 
extended in vitro culture. 
When injected into wild-
type mouse blastocysts, 
these modified fibroblasts 
contributed to multiple 
differentiated cell types 
in developing embryos, 
although none of these 
chimeric animals survived 
to birth. Although not bona 
fide ES cells, it is clear that 
the modified fibroblasts 
are multipotent and have gained the ability to self renew, 
at least in vitro.
In a separate report, Armstrong and colleagues 
expressed an oncogenic fusion protein (produced by 
the MLL-AF9 chromosomal translocation found in cer-
tain leukemias) in highly purified committed granulocyte 
macrophage progenitor (GMP) cells and then tested 
their ability to produce leukemia when injected into mice 
(Krivtsov et al., 2006). Remarkably, this single genetic 
alteration produced an oligoclonal disease resembling 
acute myeloid leukemia and characterized by a small 
number (<1%) of transplantable GMP cells in the bone 
marrow. Transcript profiling of these leukaemia-initiating 
GMPs, as well as normal HSCs and GMPs, revealed a 
group of 363 genes that are highly expressed in HSCs, 
downregulated in normal GMPs, but reactivated in leu-
kaemia-initiating GMPs. These genes appear to be 
arranged in a hierarchical relationship, so that activation 
of a few regulatory proteins and transcription factors may 
account for the overall self renewal transcript signature 
observed. Which of the 363 genes contribute directly to 
self renewal and/or other stem cell functions remains 
to be determined. Together, the work from the groups 
of Yamanaka and Armstrong demonstrates that self 
renewal and multipotency programs can be activated in 
differentiated cells through a small and discrete number 
of genetic alterations (Krivtsov et al., 2006; Takahashi 
and Yamanaka, 2006).
Figure 2. One Mode of Cancer Stem Cell Generation
Normal stem cells (left) typically divide slowly but retain the capac-
ity for apparently limitless self renewal (circular green arrow). Asym-
metric division of a stem cell produces one daughter stem cell and 
one committed progenitor (or transit-amplifying) cell that undergoes a 
limited series of divisions. The progeny of this transit-amplifying cell 
differentiate, producing a particular tissue. A stem cell may undergo 
oncogenic transformation (horizontal dashed line) and lose impor-
tant homeostatic control mechanisms while retaining the property of 
self renewal. This cancer stem cell (right) could then produce trans-
formed progenitors, whose progeny consequently fail to differentiate 
normally, or exhibit normal growth controls, resulting in tumor forma-
tion. Whereas the transformed cancer stem cell retains the property 
of self renewal and can produce new tumors in serial transplantation 
experiments, its progeny do not (Huntly and Gilliland, 2005). Grow-
ing evidence suggests that normal and transformed progenitor cells 
can, under certain circumstances, regain stem cell properties (vertical 
dashed lines) (Krivtsov et al., 2006, Morrison and Kimble, 2006).Cell 129, May 4, 2007 ©2007 Elsevier Inc. 469
It is striking that two of the four factors identified by 
Takahashi and Yamanaka are directly activated by HIF-
2α, albeit by different mechanisms. As described above, 
induction of Oct4 expression in HIF-2α knockin cells cor-
relates with profound effects on embryonic development, 
hematopoietic differentiation, and tumor growth (Covello 
et al., 2006). Interestingly, Oct4 expression has been 
detected in a variety of cancer cell lines and is induced by 
hypoxia in a HIF-2α expressing renal carcinoma cell line 
(Tai et al., 2005). These results suggest that the Oct4 locus, 
which is not expressed in normal differentiated somatic 
cells, can be derepressed in cancer cells and may pro-
mote an undifferentiated cellular phenotype. In support 
of this idea, Jaenisch and colleagues demonstrated that 
inducible expression of Oct4 in transgenic mice produced 
reversible epithelial dysplasia, a characteristic of prema-
lignant lesions (Hochedlinger et al., 2005). Together, these 
data support a role for Oct4 in promoting the proliferation 
of undifferentiated progenitor and/or stem cells, thereby 
contributing to tumor growth. In fact, RNAi-mediated 
inhibition of Oct4 expression in HIF-2α knockin terato-
mas reduced tumor size in allograft assays (Covello et al., 
2006). It is interesting that the dysplastic Oct4-expressing 
murine epithelia, as well as the HIF-2α knockin teratomas, 
showed elevated levels of β-catenin protein, suggesting 
that Oct4 expression may stimulate Wnt pathway signal-
ing in some cells. The degree to which Oct4 contributes 
to the growth of human tumors is unknown, although it is 
clearly implicated in testicular germ cell tumors (Gidekel 
et al., 2003). Presumably, Oct4 expression would not have 
to be reactivated in cancer stem cells derived from direct 
oncogenic transformation of germ stem cells, or possibly 
in other adult stem cells.
Interestingly, HIF proteins also modulate the activity 
of c-Myc, an oncogene of central importance to many 
cancers. Huang and colleagues demonstrated that HIF-
1α antagonizes c-Myc activity by competing for binding 
to the transcription factor Sp1 under hypoxic conditions, 
with consequent inhibition of c-Myc-
dependent cell-cycle progression 
(Koshiji et al., 2004). Surprisingly, HIF-
2α has the opposite effect on c-Myc, 
promoting cell-cycle progression and 
transformation by enhancing the tran-
scriptional effects of c-Myc on both 
activated and repressed target genes 
in multiple cancer cell lines, mouse 
embryonic fibroblasts, and embryonic 
cell lines (Gordan et al., 2007). HIF-2α 
potentiates c-Myc activity by enhanc-
ing its physical association with Sp1, 
Miz1, and Max, although the precise 
mechanisms regulating these events 
are not yet fully understood. These 
effects may partly explain the observa-
tion that HIF-2α specifically promotes 
the growth of pVHL-deficient renal 
clear cell carcinoma cells in xenograft 
experiments, whereas HIF-1α does not (Seagroves and 
Johnson, 2002).
HIF regulation of Notch activity may also contribute to 
cancer stem cell formation. In mammals, Notch appears 
to have oncogenic effects in some contexts (T cell acute 
lymphoblastic leukemia, intestinal tumors), and tumor 
suppressor effects in others (keratinocytes) (Weng and 
Aster, 2004; Wilson and Radtke, 2006). These different 
properties may reflect the complexity of gene families 
encoding the Notch receptor and Delta and Jagged 
ligands, and their differential regulation in specific cell 
types. Moreover, the Notch pathway is known to interact 
with other pathways that control stem cell function. For 
example, Wnt and Shh signaling are repressed in murine 
epidermal cells in a Notch-dependent manner (Wilson 
and Radtke, 2006). Interestingly, Notch has recently 
been shown to activate the expression of c-Myc, sug-
gesting an indirect mechanism whereby HIF-1α may 
regulate Notch signaling (Weng et al., 2006).
Finally, proteins regulating other stem cell functions have 
been identified as HIF targets. The human gene encoding 
the ABC glycoprotein transporter MDR1, which confers 
multidrug resistance on a variety of cancer cells, is a direct 
HIF target (Comerford et al., 2002). Another HIF-regulated 
ABC transporter, Bcrp/ABCG2, is also expressed in a 
number of stem cell types and is implicated in chemothera-
peutic drug resistance in breast cancers (Krishnamurthy et 
al., 2004). Finally, the gene encoding the enzymatic compo-
nent of human telomerase (hTERT) is induced by hypoxia 
in a HIF-dependent manner (Nishi et al., 2004). Expression 
of ABC transporters and sustained telomerase activity are 
thought to be important features of stem cell function.
We propose that HIF stabilization in hypoxic tumor 
cells may promote the adoption of stem cell proper-
ties, including self renewal and multipotency, by stim-
ulating the expression or activity of Oct4, Notch, and 
other critical signaling pathways (Figure 3). If true, it 
suggests that hypoxic tumor tissues could be a breed-
Figure 3. How HIF Activity Could Promote Generation of Cancer Stem Cells
Cells in hypoxic tumor regions stabilize HIFs and activate adaptive gene expression (see 
Figure 1). HIF activity in a rare subset of hypoxic tumor cells may enhance the expression or 
activity of other gene products including Notch, Oct4, c-Myc, ABC transporters (ABC-T), and 
telomerase to promote a stem cell-like state. Increased expression of KLF4, Sox2, and other 
factors could promote further dedifferentiation and confer stem cell-like properties, such as 
self-renewal (circular green arrow), on what was originally a transformed cell with limited 
replicative potential. Inhibition of HIF activity in the resultant cancer stem cells might block, 
or reverse, this effect.470 Cell 129, May 4, 2007 ©2007 Elsevier Inc.
Cell 129, May 4, 2007 ©2007 Elsevier Inc. 471ing ground for cancer stem cells, although these could 
certainly be derived from oncogenic transformation of 
extant adult stem cells. The results summarized in this 
review suggest multiple mechanisms by which tumor 
hypoxia could contribute to the conversion of differ-
entiated tumor cells into cancer stem cells. For exam-
ple, disrupted epigenetic silencing in a transformed 
cell may result in derepression of the Oct4 locus, ren-
dering it susceptible to regulation by HIF-2α (Covello 
et al., 2006). Potentiation of c-Myc activity by HIF-2α 
could also promote proliferation and operate in con-
cert with Oct4 to activate a self renewal gene expres-
sion program (Gordan et al., 2007). To date, there are 
no reports in the literature suggesting that KLF4 or 
Sox2 are direct (or indirect) HIF targets, although it is 
certainly possible. Given the opposing effects of HIF-
1α and HIF-2α on c-Myc transcriptional activity, the 
functional outcome of hypoxic c-Myc regulation may 
depend on the relative expression levels of HIF-1α and 
HIF-2α in a given cancer cell type (Gordan et al., 2007; 
Koshiji et al., 2004). Stabilization of HIF-1α could also 
enhance Notch function, the effects of which might 
include inhibition of differentiation, modulation of 
other stem cell signaling pathways (Wnt and Shh), and 
possibly induction of c-Myc expression (Gustafsson 
et al., 2005; Wilson and Radtke, 2006). Lastly, hypoxic 
induction of MDR1, ABCG2, and hTERT expression 
in these cells could confer other important stem cell 
characteristics (Comerford et al., 2002; Krishnamur-
thy et al., 2004; Nishi et al., 2004). The combined 
effects of hypoxia and the HIF proteins may ultimately 
impose attributes of stem cell identity on more differ-
entiated transformed cells. It should be emphasized 
that this outcome would likely be a rare event: only 
those hypoxic tumor cells which express a particular 
level of the relevant stem cell factors, particularly Oct4 
and Notch, would be expected to gain stem cell char-
acteristics.
The proposed model suggests that the effects of 
tumor hypoxia extend beyond its critically important 
role in driving angiogenesis and modulating cancer cell 
metabolism and survival. As eradicating cancer stem 
cells is increasingly recognized as an important goal in 
curing cancer, the HIF pathways are even more attrac-
tive as targets of therapeutic intervention (Semenza, 
2003). Reducing HIF activity in cancer stem cells may 
promote their differentiation, thereby reducing their 
ability to repopulate tumors after chemo and radiation 
therapies. To test this idea, it will be necessary to ablate 
the function of HIF-1α, HIF-2α, Notch, Oct4, c-Myc, and 
other pathway components in rigorously defined tumor 
models.
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